Courtenay Brinckerhoff is a partner and intellectual property lawyer with Foley & Lardner LLP. Ms. Brinckerhoff’s practice focuses on client counseling in all aspects of obtaining, licensing and enforcing patents and conducting freedom-to-operate and due diligence investigations. She is chair of the firm’s IP Law and Practice committee, immediate past vice chair of the firm’s Chemical, Biotechnology & Pharmaceutical Practice and a member of the firm's Patent Trials group, Appellate Practice and Life Sciences Industry Team. She also is involved with Foley’s Medical Device Initiative and Nutraceuticals Team. Ms. Brinckerhoff is the editor and primary author for Foley’s PharmaPatentsBlog.com.
Over the past 20 years, Ms. Brinckerhoff has represented clients before the U.S. Patent Office, the Patent Trial and Appeal Board, and the U.S. Court of Appeals for the Federal Circuit, and has been involved in complex patent matters, including a four-party interference, Inter Partes Reexaminations, Inter Partes Reviews, and ANDA litigation.
Ms. Brinckerhoff works with clients in diverse industries, including pharmaceuticals (chemical and biotechnological), human and animal food products, nutraceuticals, and medical devices. She has particular experience with transdermal pharmaceutical products (patches, gels, and liquids), oral dosage forms (including controlled/extended release formulations), enzyme-based technologies, diagnostic and therapeutic antibodies, active and passive immunization therapies, and personalized medicine.
She has served as vice chair of the firm’s Chemical, Biotechnology & Pharmaceutical Practice and is an active member of the firm's Appellate Practice and Life Sciences Industry Team.
More Legal and Business Bylines From Courtenay C. Brinckerhoff
- Biosimilar Pre-Marketing Notice Always Required - (Posted On Tuesday, December 15, 2015)
- Interference Statute Does Not Require Diligence For Re-Presenting Claims - (Posted On Thursday, December 10, 2015)
- Judge Lourie (Federal Circuit) Suggests Jepson Claims For Patent Eligibility - (Posted On Tuesday, December 08, 2015)
- Judge Dyk Would Add Reduction To Practice To Patent Eligibility Requirement - (Posted On Thursday, December 03, 2015)
- Federal Circuit Denies Rehearing In Sequenom - (Posted On Wednesday, December 02, 2015)
- Obviousness Versus Obviousness-Type Double Patenting - (Posted On Tuesday, November 24, 2015)
- Federal Circuit Interprets Two Important Infringement Provisions - (Posted On Thursday, November 19, 2015)
- Federal Circuit To Revisit On Sale Bar Triggered By Contract Manufacture - (Posted On Monday, November 16, 2015)
- USPTO Proposes New IDS Framework - (Posted On Thursday, November 12, 2015)
- USPTO Plans To Hike Patent Fees - (Posted On Tuesday, November 10, 2015)
Courtenay C. Brinckerhoff and her work on Foley & Lardner's Pharma Patents blog has been selected for a National Law Review Go-To Thought Leadership Award. Ms. Brinckerhoff offers expert analysis on an area of law that can be very complicated, breaking down developments at the U.S. Patent Office, the Patent Trial and Appeal Board, and the U.S. Court of Appeals for the Federal Circuit. Her insights on patent litigation, especially pharmaceutical patents, and how decisions impact the larger landscape are of particular interest to our readers. You can subscribe to Foley & Lardner's blog, PharmaPatents, here.